Journal
BIOANALYSIS
Volume 10, Issue 11, Pages 815-823Publisher
FUTURE SCI LTD
DOI: 10.4155/bio-2018-0010
Keywords
biologic; capillary blood microsampling; DBS; dried blood spot; therapeutic monoclonal antibody
Funding
- Pfizer
- Pfizer (Wyeth)
- Amgen
- AbbVie
- UCB
- BMS
- Genmab
Ask authors/readers for more resources
Aim: For assessment of concentrations of biopharmaceuticals, for example, therapeutic drug monitoring, dried blood sampling of capillary blood is a convenient alternative to traditional venepuncture sampling. We investigated an alternative to dried blood spot collection on filter paper: sampling capillary blood using the Mitra((R)) microsampler. Materials and Methods: Therapeutic monoclonal antibodies were spiked in whole blood, sampled using filter paper and Mitra microsampler and concentrations measured using specific ELISAs. Results: Good recoveries of adalimumab, infliximab, ustekinumab, vedolizumab, tocilizumab, natalizumab and rituximab were found up to 1 month of storage at room temperature, averaging 95.2% for the Mitra microsampler and 92.9% for Whatman((R)) paper. Both hemoglobin and potassium yield satisfactory estimates for the volume of the cellular fraction of blood samples in combination with the Mitra microsampler. Conclusion: We established practical protocols for the estimation of serum/plasma concentrations of therapeutic antibodies via capillary blood microsampling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available